<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766532</url>
  </required_header>
  <id_info>
    <org_study_id>H-2008-0144</org_study_id>
    <nct_id>NCT00766532</nct_id>
  </id_info>
  <brief_title>Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?</brief_title>
  <official_title>Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Question: Do Aromatase Inhibitors Decrease Intestinal Calcium Absorption?

      Study Design: Postmenopausal women with early stage breast cancer initiating aromatase
      inhibitor adjuvant therapy will participate in this two-month study. The primary study
      outcome is the change in intestinal calcium absorption following such therapy. Secondary
      outcomes are the changes in bone resorption markers and musculoskeletal signs and symptoms
      after initiation of therapy.

      We will interview women and review their medical records to determine eligibility. Eligible
      subjects will undergo two calcium absorption studies. The first study will determine their
      baseline calcium absorption, and the second study will occur after taking an aromatase
      inhibitor daily for at least 6 weeks. Women will present to the research unit in the early
      morning and receive an oral and intravenous stable calcium tracer with breakfast. Over the
      next 24 hours, we will collect all urine for measurement of its calcium content. During each
      inpatient stay, we will assess musculoskeletal symptoms by questionnaire and joint
      examination. Each woman will complete a four-day diet diary twice during the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in Intestinal Calcium Absorption Related to Aromatase Inhibitor Therapy</measure>
    <time_frame>baseline and 6 weeks later</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>intestinal calcium absorption</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <condition>Fracture</condition>
  <arm_group>
    <arm_group_label>aromatase inhibitor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aromatase inhibitor therapy for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor</intervention_name>
    <description>Any aromatase inhibitor started as initial adjuvant therapy</description>
    <arm_group_label>aromatase inhibitor therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women at least 5 years past menopause, defined as date of last menses or bilateral
             oophorectomy

          -  Newly diagnosed breast cancer and starting an AI as initial adjuvant therapy

        Exclusion Criteria

          -  Recent, current or planned chemotherapy for breast cancer, as this may have
             independent effects on intestinal health, calcium homeostasis and bone turnover

          -  Allergy or intolerance to orange juice, as one isotope is given with orange juice

          -  Current use of over-the-counter or prescription antacids, as they may influence Ca-Ab

          -  Intestinal conditions associated with malabsorption or low gastric acid levels
             including Crohn's disease, ulcerative colitis, pernicious anemia, bacterial
             overgrowth, celiac sprue, chronic diarrhea or use of antibiotics within the past
             month

          -  Known Stage 4 or 5 Chronic Kidney Disease, defined as an estimated GFR &lt;30 cc/minute

          -  Use of medications known to interfere with calcium or vitamin D metabolism, including
             oral steroids or anticonvulsants

          -  Significant lymphedema precluding adequate intravenous access
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE. Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.</citation>
    <PMID>22350731</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 13, 2012</lastchanged_date>
  <firstreceived_date>October 2, 2008</firstreceived_date>
  <firstreceived_results_date>July 6, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Postmenopausal women with early stage breast cancer and planning to start aromatase inhibitor therapy.</recruitment_details>
      <pre_assignment_details>Participants completed a four-day food diary</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm Title- Aromatase Inhibitor Therapy</title>
          <description>calcium absorption was measured among subjects at baseline and after taking aromatase inhibitor therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66" spread="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intestinal Calcium Absorption Related to Aromatase Inhibitor Therapy</title>
        <description>intestinal calcium absorption</description>
        <time_frame>baseline and 6 weeks later</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>12 subjects provided informed consent but two dropped and did not undergo calcium absorption study visits. 10 subjects completed all calcium absorption study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor Therapy</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Intestinal Calcium Absorption Related to Aromatase Inhibitor Therapy</title>
            <description>intestinal calcium absorption</description>
            <units>percent calcium absorption</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16" spread="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen Hansen</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-0517</phone>
      <email>keh@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
